Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Skowronski, Danuta M ^a,b   Janjua, Naveed Z ^a,b   De Serres, Gaston ^c,d   Sabaiduc, Suzana ^a   Eshaghi, Alireza ^e   Dickinson, James A ^f   Fonseca, Kevin ^f,g   Winter, Anne Luise ^e   Gubbay, Jonathan B ^e,h,i   Krajden, Mel ^a   Petric, Martin ^a   Charest, Hugues ^c,j   Bastien, Nathalie ^k   Kwindt, Trijntje L ^b   Mahmud, Salaheddin M ^l   Van Caeseele, Paul ^l,m   Li, Yan ^k,l  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e PUBLIC HEALTH ONTARIO   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^l UNIVERSITY OF MANITOBA   (Canada)

^m CADHAM PROVINCIAL LABORATORY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; IVR 165; UNCLASSIFIED DRUG; VIRUS DNA;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; CANADA; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GENOTYPE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNIZATION; INFLUENZA A (H3N2); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; MUTATION; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ACTIVATION; VIRUS ISOLATION; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; INFANT; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR GENETICS; NEWBORN; PRESCHOOL CHILD; PROTEIN CONFORMATION; SEASON; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; SEASONS; YOUNG ADULT;

EID: 84899838197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092153     Document Type: Article

References (51)

1. Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter AL, et al. (2013) Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill 18(5): 7-16. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20394. Accessed 2013 Dec 7.
2. Public Health Agency of Canada. FluWatch. Available: http://www.phac- aspc.gc.ca/fluwatch/12-13/index-eng.php. Accessed 2013 Dec 7.
3. National Advisory Committee on Immunization (NACI) (2013) Statement on seasonal influenza vaccine for 2013-2014. Can Commun Dis Rep 39:1-37. Available: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-4/index-eng.php. Accessed 2013 Dec 7.
4. Bresee J, Hayden FG (2013) Epidemic influenza - responding to the expected but unpredictable. N Engl J Med 368: 589-592; published online February 14. Available: http://www.nejm.org/doi/full/10.1056/NEJMp1300375. Accessed 2013 Dec 7.
5. Centers for Disease Control and Prevention (CDC). FluView. Atlanta, GA: CDC. Available: http://www.cdc.gov/flu/weekly/pastreports.htm. Accessed 2013 Dec 7.
6. BC Centre for Disease Control (2013) British Columbia Annual Summary of Reportable Diseases 2012. Available: http://www.bccdc.ca/util/about/annreport/ default.htm. Accessed 2013 Dec 7.
7. BC Centre for Disease Control (2013) Influenza immunization coverage in BC health care facilities. Available: http://www.bccdc.ca/imm-vac/ BCImmunizationCov/flucoverage/default.htm. Accessed 2013 Dec 7.
8. Centers for Disease Control and Prevention (CDC) (2013) Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep 62: 119-123. Available: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm6207a2.htm?s-cid = mm6207a2-w. Accessed 2013 Dec 7.
9. Valenciano M, Kissling E (2013) Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill 18: 3. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId =20400. Accessed 2013 Dec 7.
10. World Health Organization. WHO recommendations on the composition of influenza virus vaccines. Available: http://www.who.int/influenza/vaccines/ virus/recommendations/en/index.html. Accessed 2013 Dec 7.
11. National Institute for Biological Standards and Control (2012) Influenza Reagent - Influenza virus infectious IVR-165. Available: http://www.nibsc.org/ documents/ifu/11-220.pdf. Accessed 2013 Dec 7.
12. Skowronski DM, Gilbert M, Tweed SA, Petric M, Li Y, et al. (2005) Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005. Can Commun Dis Rep 31: 181-191. Available: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05vol31/dr3118a-eng.php. Accessed 2013 Dec 7.
13. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, et al. (2007) Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 25: 2842-2851. (Pubitemid 46412567)
14. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, et al. (2009) Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 199: 168-179.
15. Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, et al. (2012) Estimates of influenza vaccine effectiveness for 2007-08 from Canada's sentinel surveillance system: Cross-protection against major and minor variants. J Infect Dis 205: 1858-1868.
16. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, et al. (2010) Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med. 7(4): e1000258.
17. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, et al. (2011) Effectiveness of AS03-adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342: c7297. doi:10.1136/bmj.c7297.
18. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, et al. (2012) A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-11 season. Clin Infect Dis 55: 332-342.
19. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, et al. (2014) Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis; doi:10.1093/infdis/jiu048.
20. National Advisory Committee on Immunization (NACI) (2012) Statement on seasonal influenza vaccine for 2012-2013. Can Commun Dis Rep 38:1-36. Available: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-2/index-eng.php. Accessed 2013 Dec 7.
21. Katz JM, Hancock K, Xu X (2011) Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 9: 669-683.
22. Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM (1999) Predicting the evolution of human influenza A. Science 286: 1921-1925. (Pubitemid 129515893)
23. Brownlee GG, Fodor E (2001) The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Phil Trans R Soc Lond 356: 1871-1876. (Pubitemid 34099092)
24. World Health Organization (2011) WHO information for molecular diagnosis of influenza virus in humans - update. Available: http://www.who.int/influenza/ resources/documents/molecular-diagnosis-influenza-virus-humans-update-201108. pdf. Accessed 2013 Dec 7.
25. Statistics Canada. Table 105-0502 - Health indicator profile, two year period estimates, by age group and sex, Canada, provinces, territories, health regions (2012 boundaries) and peer groups, occasional, CANSIM [database]. Available: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/ health102beng.htm. Accessed 2013 Dec 7.
26. Broemeling AM, Watson DE, Prebtani F (2008) Population patterns of chronic health conditions, comorbidity and healthcare use in Canada: implications for policy and practice. Healthc Q 11(3): 70-76.
27. Sauter NK, Hanson JE, Glick GD, Brown JH, Crowther RL, et al. (1992) Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography. Biochemistry 31: 9609-9621.
28. The PyMOL Molecular Graphics System, Version 1.6 Schrödinger, LLC.
29. European Centre for Disease Prevention and Control (ECDC) (2014) Influenza virus characterisation. Summary Europe, September 2013. Surveillance report. Stockholm: ECDC. Available: http://ecdc.europa.eu/en/publications/ Publications/influenza-virus-characterisation-sep-2013.pdf. Accessed 2014 Feb 4.
30. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, et al. (2010) Structural basis of pre-existing immunity to the 2009 H1N1 pandemic influenza virus. Science 328: 357-360.
31. Treanor J (2004) Weathering the influenza vaccine crisis. N Engl J Med 351: 2037-2040.
32. Robertson JS (1993) Clinical influenza virus and the embryonated hen's egg. Rev Med Virol 3: 97-106.
33. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM (1993) The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol 74: 2047-2051. (Pubitemid 23299881)
34. Katz JM, Webster RG (1989) Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 160: 191-198. (Pubitemid 19189009)
35. Rocha EP, Xu X, Hall HE, Allen JR, Regnery HL, et al. (1993) Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J Gen Virol 74: 2513-2518. (Pubitemid 23332317)
36. Ndifon W, Wingreen NS, Levin SA (2009) Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A 106: 8701-8706.
37. Popova L, Smith K, West AH, Wilson PC, James JA, et al. (2012) Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One 7: e41895. DOI: 10.1371/journal. pone.0041895.
38. Jin H, Zhou H, Liu H, Chan W, Adhikary L, et al. (2005) Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift from A/Panama/2007/99. Virology 336: 113-119. (Pubitemid 40603676)
39. Chen Z, Zhou H, Jin H (2010) The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 28: 4079-4085.
40. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GCM, et al. (2013) Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342: 976-979. Doi: 10.1126/science.1244730.
41. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 12: 36-44.
42. Smith DJ, Forrest S, Ackley DH, Perelson AS (1999) Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 96: 14001-14006 .
43. World Health Organization. Influenza updates. Available: http://www.who.int/influenza/surveillance-monitoring/updates/en/. Accessed 2014 Jan 29.
44. Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Gardy JL, et al. (2012) Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One 7(6): e38929. doi: 10.1371/journal.pone.0038929.
45. Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, et al. (2011) Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J 30: 833-839.
46. Gilca V, De Serres G, Hamelin ME, Boivin G, Quakki M et al. (2011) Antibody persistence and response to 2010-11 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 30: 35-41 Epub 2011 Nov 7.
47. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, et al. (2013) Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 11: 153. Available: http://www.biomedcentral. com/1741-7015/11/153. Accessed 2013 Dec 7.
48. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA (2009) Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 27: 6546-6549.
49. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, et al. (2007) Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 36: 623-631 (Pubitemid 47244566)
50. Gilmour H, Hofmann N (2010) H1N1 vaccination. Health Reports 21(4). Statistics Canada, Catalogue no. 82-003-XPE. Available: http://www.statcan.gc. ca/pub/82-003-x/2010004/article/11348-eng.pdf. Accessed 2013 Dec 7.
51. De Serres G, Skowronski DM, Wu XW, Ambrose CS (2013) The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomized double-blind placebo-controlled trials. Euro Surveill 18(37). pii:20585. Available: http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=20585. Accessed 2013 Dec 7.